Sanofi (SNY)
After hours:
| Previous close | 57.46 |
| Open | 56.99 |
| Bid | 56.72 x 300 |
| Ask | 56.78 x 300 |
| Day's range | 56.59 - 57.06 |
| 52-week range | 42.63 - 58.97 |
| Volume | |
| Avg. volume | 2,206,866 |
| Market cap | 144.436B |
| Beta (5Y monthly) | 0.42 |
| PE ratio (TTM) | 30.68 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 2.04 (3.59%) |
| Ex-dividend date | 09 May 2024 |
| 1y target est | N/A |
- GlobeNewswire
Press Release: Sanofi, RadioMedix, and Orano Med announce licensing agreement on next-generation radioligand medicine for rare cancers
Sanofi, RadioMedix, and Orano Med announce licensing agreement on next-generation radioligand medicine for rare cancers Paris, France, and Houston, Texas, September 12, 2024. As part of its effort to develop innovative treatments for people living with rare cancers, Sanofi has entered into an exclusive licensing agreement with RadioMedix, Inc., a US clinical-stage biotechnology company developing radiopharmaceuticals for PET imaging and targeted alpha therapy (TAT) against unmet medical needs in
- GlobeNewswire
Press Release: Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU
Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU Confirming the results of CUPID-A, this second pivotal study in biologic-naïve patients met primary and key secondary endpoints, showing treatment with Dupixent resulted in a nearly 50% reduction in itch and urticaria activity scores compared to placeboMore than 300,000 people in the US suffer from chronic spontaneous urticaria (CSU) that is inadequately controlled by antihistaminesData will support
- GlobeNewswire
Press Release: Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal study
Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal study Study met the primary and all key secondary endpoints in adults with moderate-to-severe disease; five times more patients achieved sustained disease remission with Dupixent than placeboDupixent is the first medicine to show significant steroid-sparing effect in this debilitating and life-threatening disease If approved, Dupixent would be the f
